Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Colorcon
McKinsey
Boehringer Ingelheim
Johnson and Johnson

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Claims for Patent: 10,099,009

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 10,099,009
Title:Central venous catheter with reverse flush port
Abstract: A catheter having a secondary port that enables flushing a fluid from a portion of the catheter. The secondary port is disposed along the length of the catheter tube so as to be near an entry point of the catheter into a patient\'s body. A clamp is disposed adjacent to the secondary port on a side proximate to the patient\'s body. The secondary port and clamp enable flushing of a fluid from a portion of the catheter that is external to the patient\'s body and disposal of a clot- or obstruction-dissolving agent into the external portion of the catheter. Upon removal of the clot or obstruction, the secondary port and clamp enable removal of the dissolving agent and replenishing the fluid in the external portion of the catheter to resume provision of the fluid to the patient.
Inventor(s): Anderson; Judith L. (Shawnee, KS)
Assignee:
Application Number:15/064,224
Patent Claims:1. A method for removing a clot or obstruction from a central venous catheter, the method comprising: administering a fluid to a living body via a catheter having a proximal portion and a distal portion defined by a port disposed therebetween along a length of a catheter tubing, the proximal portion being configured for insertion into the living body and the distal portion having a free end configured to couple to a fluid-delivery apparatus; actuating a flow-restricting means to a closed position to restrict a flow of the fluid from the distal to the proximal portion of the catheter, the flow-restricting means being disposed on the proximal portion in close proximity to the port; flowing a flushing solution into the distal portion via the port to replace the fluid in the distal portion with the flushing solution, the flushing solution being configured to dissolve the clot or obstruction formed in the proximal portion of the catheter; actuating the flow-restricting means to an open position to enable fluid communication of the flushing solution from the distal portion to the proximal portion of the catheter; diffusing the flushing solution in the distal portion into the fluid in the proximal portion over a period of time thereby forming a mixture of the flushing solution and the fluid within the distal and proximal portions of the catheter, the diffusing placing the flushing solution in communication with the clot or obstruction to enable the flushing solution to dissolve the clot or obstruction; determining the presence of the clot or obstruction by applying one or both of a positive and a negative pressure on the mixture; actuating the flow-restricting means to the closed position when the clot or obstruction is determined to no longer be present; removing the mixture of the flushing solution and the fluid from the distal portion of the catheter using the port and the free end of the distal portion; refilling the distal portion with the fluid using the free end of the distal portion and the port; and actuating the flow-restricting means to the open position to resume administration of the fluid to the living body.

2. The method of claim 1, further comprising: applying a negative fluid pressure on the catheter to draw the mixture of the fluid and the flushing solution from the proximal portion into the distal portion.

3. The method of claim 2, wherein applying a negative fluid pressure on the catheter to draw the mixture of the fluid and the flushing solution from the proximal portion into the distal portion comprises aspirating a bodily fluid from the living body at least partially into the catheter.

4. The method of claim 1, wherein the fluid comprises one or more of a medicinal fluid, a hydration fluid, and a nutrition fluid.

5. The method of claim 1, wherein fluid communication of the flushing solution from the distal portion to the proximal portion of the catheter includes applying a fluid pressure on the catheter to at least partially flow the flushing solution into the proximal portion.

6. The method of claim 1, wherein substantially none of the fluid is administered to the living body between actuating the flow-restricting means to the closed position to restrict the flow of the fluid from the distal to the proximal portion of the catheter and actuating the flow-restricting means to the open position to resume administration of the fluid to the living body.

7. The method of claim 1, wherein removing the mixture of the flushing solution and the fluid from the distal portion of the catheter using the port and the free end of the distal portion and refilling the distal portion with the fluid using the free end of the distal portion and the port further comprises: opening the port or the free end to enable a gas to enter the distal portion; draining the mixture from the distal portion via another of the port and the free end.

8. The method of claim 1, wherein removing the mixture of the flushing solution and the fluid from the distal portion of the catheter using the port and the free end of the distal portion and refilling the distal portion with the fluid using the free end of the distal portion and the port further comprises: flowing the fluid into the distal portion using one of the port and the free end; draining the mixture from the distal portion via another of the port and the free end.

9. The method of claim 1, wherein the flushing solution is one or more of tPA (Tissue plasminogen activator), rtPA (recombinant tissue plasminogen activator), alteplase, and recombinant urokinase.

Details for Patent 10,099,009

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech ACTIVASE alteplase VIAL; SINGLE-USE 103172 001 1987-11-13   Start Trial 2035-03-12 RX search
Genentech ACTIVASE alteplase VIAL; SINGLE-USE 103172 002 1987-11-13   Start Trial 2035-03-12 RX search
Genentech CATHFLO ACTIVASE alteplase VIAL 103172 003 1987-11-13   Start Trial 2035-03-12 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Johnson and Johnson
AstraZeneca
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.